News
Alligator Bioscience and Orion Corporation announce the initiation of the second program of their Immuno-oncology Research Collaboration relating to bispecific antibodies
Alligator Bioscience announces an expansion to its research collaboration and license agreement with Orion Corporation, a global pharmaceutical company based in Finland, to discover and develop together new bispecific antibody cancer therapeutics
The collaboration has been expanded to add the development of a second bispecific antibody using Alligator’s proprietary bispecific RUBY platform, where Alligator will provide validated monospecific binders for one target and Orion will do the same for the other targets.
Type: industry
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
